BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25933544)

  • 1. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
    Qi X; Fan Y; He H; Wu Z
    Carbohydr Polym; 2015 Aug; 126():231-9. PubMed ID: 25933544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bio-stimuli-responsive multi-scale hyaluronic acid nanoparticles for deepened tumor penetration and enhanced therapy.
    Huo M; Li W; Chaudhuri AS; Fan Y; Han X; Yang C; Wu Z; Qi X
    Carbohydr Polym; 2017 Sep; 171():173-182. PubMed ID: 28578951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells.
    Kesharwani P; Xie L; Banerjee S; Mao G; Padhye S; Sarkar FH; Iyer AK
    Colloids Surf B Biointerfaces; 2015 Dec; 136():413-23. PubMed ID: 26440757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
    Zucker D; Barenholz Y
    J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
    Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Lee JH; Kim K; Kwon IC; Kim DD
    Biomaterials; 2011 Oct; 32(29):7181-90. PubMed ID: 21733572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
    Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
    J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
    Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
    J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid-modified polyamidoamine dendrimer G5-entrapped gold nanoparticles delivering METase gene inhibits gastric tumor growth via targeting CD44+ gastric cancer cells.
    Li YF; Zhang HT; Xin L
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1463-1473. PubMed ID: 29858680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
    Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
    Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
    Choi KY; Yoon HY; Kim JH; Bae SM; Park RW; Kang YM; Kim IS; Kwon IC; Choi K; Jeong SY; Kim K; Park JH
    ACS Nano; 2011 Nov; 5(11):8591-9. PubMed ID: 21967065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.
    Yang XY; Li YX; Li M; Zhang L; Feng LX; Zhang N
    Cancer Lett; 2013 Jul; 334(2):338-45. PubMed ID: 22776563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
    Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
    Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
    He M; Zhao Z; Yin L; Tang C; Yin C
    Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved tumor targetability of Tat-conjugated PAMAM dendrimers as a novel nanosized anti-tumor drug carrier.
    Yan C; Gu J; Hou D; Jing H; Wang J; Guo Y; Katsumi H; Sakane T; Yamamoto A
    Drug Dev Ind Pharm; 2015 Apr; 41(4):617-22. PubMed ID: 24564798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient targeted gene delivery by a novel PAMAM/DNA dendriplex coated with hyaluronic acid.
    Urbiola K; Sanmartín C; Blanco-Fernández L; Tros de Ilarduya C
    Nanomedicine (Lond); 2014 Dec; 9(18):2787-801. PubMed ID: 24959932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
    Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
    Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.
    Chang G; Ci T; Yu L; Ding J
    J Control Release; 2011 Nov; 156(1):21-7. PubMed ID: 21777632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A self-assembly nanodrug delivery system based on amphiphilic low generations of PAMAM dendrimers-ursolic acid conjugate modified by lactobionic acid for HCC targeting therapy.
    Shen Z; Li B; Liu Y; Zheng G; Guo Y; Zhao R; Jiang K; Fan L; Shao J
    Nanomedicine; 2018 Feb; 14(2):227-236. PubMed ID: 29128661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.